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Background: Glioblastoma (GBM) is the most common malignant brain cancer occurring in adults, and is associated
with dismal outcome and few therapeutic options. GBM has been shown to predominantly disrupt three core pathways
through somatic aberrations, rendering it ideal for precision medicine approaches.
Methods: We describe a 35-year-old female patient with recurrent GBM following surgical removal of the primary
tumour, adjuvant treatment with temozolomide and a 3-year disease-free period. Rapid whole-genome sequencing
(WGS) of three separate tumour regions at recurrence was carried out and interpreted relative to WGS of two regions of
the primary tumour.
Results: We found extensive mutational and copy-number heterogeneity within the primary tumour. We identiﬁed a
TP53mutation and two focal ampliﬁcations involving PDGFRA, KIT and CDK4, on chromosomes 4 and 12. A clonal IDH1
R132H mutation in the primary, a known GBM driver event, was detectable at only very low frequency in the recurrent
tumour. After sub-clonal diversiﬁcation, evidence was found for a whole-genome doubling event and a translocation
between the ampliﬁed regions of PDGFRA, KIT and CDK4, encoded within a double-minute chromosome also incorpor-
ating miR26a-2. The WGS analysis uncovered progressive evolution of the double-minute chromosome converging on
the KIT/PDGFRA/PI3K/mTOR axis, superseding the IDH1mutation in dominance in a mutually exclusive manner at recur-
rence, consequently the patient was treated with imatinib. Despite rapid sequencing and cancer genome-guided therapy
against ampliﬁed oncogenes, the disease progressed, and the patient died shortly after.
Conclusion: This case sheds light on the dynamic evolution of a GBM tumour, deﬁning the origins of the lethal sub-
clone, the macro-evolutionary genomic events dominating the disease at recurrence and the loss of a clonal driver. Even
in the era of rapid WGS analysis, cases such as this illustrate the signiﬁcant hurdles for precision medicine success.
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Glioblastoma (GBM) is the most common malignant brain
cancer occurring in adults and is associated with poor prognosis
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GBM tumours recur after surgery, radiotherapy and chemother-
apy, with a median time to recurrence of 7 months [1].
Accumulating evidence suggests that treatment failure in
cancer may be driven by intra-tumour heterogeneity (ITH), and
branched tumour evolution involving genetically distinct sub-
clones [2]. Recent studies have documented widespread ITH in
GBM. Sottoriva et al. [3] found that each individual tumour can
harbour multiple distinct copy-number proﬁles and transcrip-
tomic subtypes simultaneously. Johnson et al. [2] revealed spatial
and temporal heterogeneity in GBM, conﬁrmed the importance
of TP53 and IDH1 as early driver mutations [4, 5], and demon-
strated the impact of temozolomide (TMZ) treatment on tumour
evolution, with 6 of 10 tumours showing evidence of TMZ-
induced hypermutation at recurrence.
In order to fully assess ITH within the life history of a single
tumour and attempt to offer the patient a cancer genome-
guided therapy, we implemented rapid multi-region whole-
genome sequencing (WGS) in a patient with recurrent GBM.
This analysis reveals the temporal and spatial evolution of a
GBM tumour, deﬁning the origins of the lethal sub-clone from
a sub-clone in the primary tumour and the associated macro-
evolutionary genomic events dominating the disease at recur-
rence, confounding treatment success.
methods
ethics
Written informed consent was obtained from the patient in the Hospitaux
Universitaires de Geneve ‘Analyse de la reponse immunologique contre les
tumeurs cerebrales’ translational approved protocol IRB 03-126. Tumour
material was analysed under the UCL-Cancer Institute and Pathology
biobank (UCLHRTB 10/H1306/42). The patient provided written informed
consent to tumour sequencing analysis within a compassionate setting. The
study was conducted according to the provisions of the Declaration of
Helsinki and the Good Clinical Practice Guidelines of the International
Conference on Harmonization.
WGS data processing and analysis
WGS was carried out by Illumina, UK. Mutation calling and ﬁltering was
carried out using VarScan2 as described [6], annotation of coding mutations
were carried out using ANNOVAR [7]. Structural variant (SV) breakpoint
mechanism classiﬁcation was carried out according to the criteria deﬁned in
Yang et al. [8]. Reconstruction of the putative double-minute chromosomes
was carried out as described in Sanborn et al. [9] and breakpoints mapping
to the focal ampliﬁcations were validated by PCR and Sanger Sequencing.
Copy-number variation (CNV) analysis was carried out on the WGS data.
Purity, ploidy and allele-speciﬁc copy-number estimates were obtained with
Sequenza [10]. Clonal analysis was carried out as described in Bolli et al.
[11], estimating the cancer cell fraction (CCF) by integrating variant allele
frequency estimates with copy number, purity and ploidy estimates. Single-
sample and multi-sample Dirichlet process clustering was carried out using
the DPpackage R package [12]. In this work, mutations are referred to as
‘sub-clonal’ if their CCF indicates they are present in only a subset of cancer
cells within a given sample (CCF <1). Mutations present in all cancer cells of
a given sample (CCF∼ 1) are referred to as ‘clonal’. Genome doubling (GD)
was determined from the comparison of the sequencing of the grade II and
the grade IV regions and by considering the mutations located in the
portion of the genome where a clear doubling of the number of alleles was
detected, see supplementary Information, available at Annals of Oncology
online, for details. All data analysis was carried out in R version 3.0.2, all
P values are two sided.
results
clinical case report
A 35-year-old female presented with partial complex seizures in
January 2007, increasing in frequency after the delivery of her
second child in September 2007 (Figure 1A). MRI carried out in
June 2008, revealed a right temporal mass (6 × 6.7 × 4.5 cm) with
slight contrast enhancement. She underwent complete removal of
the tumour on 3 July 2008 and the diagnosis of WHO grade IV
astrocytoma (GBM) was established (the tumour consisted of a
grade II and grade IV histological components). She received con-
comitant treatment with irradiation (60 Gy in 30 fractions) and
TMZ, followed by 6 monthly cycles of TMZ (200 mg/m2 D1–D5)
until March 2009. She was free of symptoms for 2 years but
partial seizures reappeared in early 2011. A further MRI showed a
multi-focal recurrence in the right temporal area extending to the
thalamus and the corpus callosum. Considering the long disease-
free interval (3 years) between ﬁrst treatment and recurrence,
TMZ at a similar dose and schedule was prescribed again.
In March 2012, she presented with acute headache and intra-
cranial hypertension. MRI showed massive progression mainly
in the right frontal area with risk of herniation. She underwent
partial removal of the tumour on 29 March 2012. The histology
conﬁrmed grade IV astrocytoma with MGMT gene promoter
methylation. She received bevacizumab and TMZ; after transi-
ent clinical improvement, her clinical condition deteriorated
and TMZ was replaced by 800 mg imatinib daily, guided by the
WGS data, sequenced and reported within 7 days by Illumina,
indicating ampliﬁcation of KIT and PDGFRA. The tumour pro-
gressed rapidly on therapy and she died 3 months after the
second surgical debulking procedure.
whole-genome sequencing
Archival formalin-ﬁxed parafﬁn-embedded (FFPE) specimens
of the grade II and IV primary samples along with three fresh-
frozen samples from the recurrence and a germline reference
were WGS to a depth of 30× (∼1.3 × 106 paired reads per
sample; supplementary Table S1 in supplementary Information,
available at Annals of Oncology online). The three recurrence
regions were homogeneous at the SNV level indicating limited
clonal variation in the recurrence; however, the SNV calling was
hampered by stromal contamination (supplementary Table S1,
available at Annals of Oncology online). The three recurrent
regions, referred to as A1, A2 and A3, respectively, were merged
in silico in a single alignment ﬁle, termed As, to increase the
resolution and improve the capacity to deﬁne the evolutionary
trajectory of the recurrence specimen. 1271 and 1935 high-
conﬁdence somatic silent and non-silent SNVs were identiﬁed
in the grade II and IV regions, respectively, and 1435 in the re-
currence specimen. When comparing the grade II and grade IV
to the recurrence, the grade IV shared 338 mutations with the
recurrence not found in the grade II region, while the grade II
only shared one mutation with the recurrence not found in the
grade IV region (Figure 1B, coding mutations only in supple-
mentary Figure S1, available at Annals of Oncology online,
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detailed mutation information in supplementary File, available
at Annals of Oncology online). Given that the grade II region
exhibited fewer private mutations (69/1271, Figure 1B and C),
this indicates that it most closely resembles the most recent
common ancestor, and that the recurrence specimen evolved
from the grade IV region.
extensive mutational variation found between
grade II and grade IV regions
Several clonal mutations were found in both primary lesions
suggesting a shared clonal origin. These include a TP53 Y220C
mutation, a frame shift mutation in ATRX (K1871fs) and an
IDH1 mutation, R132H. These genes have previously been
described as driver events for GBM [4, 13], and ATRX muta-
tions has been shown to co-occur with TP53 and IDH1 muta-
tions [2], and to be a driver of alternative telomere lengthening
[14]. Clustering the mutation CCFs in the grade II and grade IV
regions revealed six distinct clusters (Figure 1D). Most muta-
tions were identiﬁed as clonal in both primary lesions or as
clonal in one but missing from the other (clusters 1, 3 and 6).
However, we also found 202 mutations that were clonal in the
grade IV but sub-clonal in the grade II (cluster 2), and two clus-
ters of mutations (4 and 5) that were sub-clonal in the grade IV
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Figure 1. Timeline and clonal structure. Timeline of the patient’s disease from diagnosis to death (A) showing timing of the temozolomide (TMZ), bevacizu-
mab (BEV) and imatinib treatments. Timeline is not drawn to scale in terms of length of time. A Euler–Venn diagram (B) displaying the overlaps of non-silent
and silent mutations in the joint recurrence cohort and the grade II and grade IV samples. A mutation spectrum of non-synonymous mutations is illustrated as
a heatmap of the detected mutations in the two primary tumour sectors and in the joint three recurrence samples (C). Squares in light grey (yellow online) re-
present mutations detected in sub-clonal populations in the speciﬁc sector while dark grey (red online) squares represent the presence of the mutation in the
clonal population of the respective sector. (D) Two-dimensional clustering of mutations in the grade II and grade IV specimens. The axis correspond the
cancer cell fraction (CCF), describing the fraction of tumour cells carrying the mutation. The ordinate corresponds to grade IV specimen and the abscissa corre-
sponds to grade II specimen. Clusters present on the upper right of the plot correspond to clonal mutations present in both specimen; clusters located in the
upper left represent clonal mutations unique of the grade IV and the bottom right correspond to clonal mutations unique of the grade II specimen. The
numbers close to each cluster represent the number of non-silent mutations present in the respective cluster, gene symbols represent speciﬁc silent mutations
present in the cluster.
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and absent in the grade II. The cluster 2 mutations likely re-
present a persistent sub-clone within the grade II region that
gave rise to the grade IV region, while clusters 4 and 5 may have
arisen independently in the grade IV, consistent with further
sub-clonal evolution occurring during disease progression.
primary tumour shows heterogeneous acquisition
of copy-number changes
CNV and SV analyses identiﬁed a number of shared events in
the primary regions (supplementary Table S2, available at
Annals of Oncology online), including copy-neutral loss of het-
erozygosity on chromosome 17p following TP53 mutation (sup-
plementary Figure S2A and B, available at Annals of Oncology
online); CDK6 and MET ampliﬁcation via gain of 7q; and
two high-level focal ampliﬁcations (supplementary Figure S3,
available at Annals of Oncology online) of 4q12 (encoding
PDGFRA and KIT) and 12q13.3-q14.1 (encoding CDK4, AVIL
and miR-26a-2).
ITH was also detected by CNV and SV analyses (supplemen-
tary Figure S4, available at Annals of Oncology online):
CDKN2A/B loss and other CNVs (gain of 6p, 19p and 20p; loss
of 10q, 12q, 13, 16q, 17q and 22) were detected only in the grade
IV sample. Furthermore, the 4q12 and 12q13.3–14.1 focal
ampliﬁcations were linked by numerous translocations in the
grade IV but not in the grade II sample (supplementary Figures
S5 and S6, available at Annals of Oncology online).
Allele-speciﬁc CNV analysis revealed that the grade IV region
was predominantly tetraploid, while the grade II region was
largely diploid. Mutations in the grade IV region also exhibited
a bimodal variant allele frequency distribution consistent with
a GD event, exclusively in the grade IV region (supplementary
Figure S7, available at Annals of Oncology online). As previously
reported [15], GD is permissive for chromosome instability
(CIN) and accelerated cancer genome evolution. Consistent
with a GD event in the grade IV region followed by chromo-
some losses due to increasing CIN [15], ﬂow cytometry on the
fresh tissue of the three recurrence samples revealed a DNA
index of 1.60, 1.58 and 1.55 for each recurrence region (supple-
mentary Figure S8, available at Annals of Oncology online).
chromosome 4 rearrangements and evolution
of a double-minute chromosome
Copy-number analysis of the recurrence tumour revealed focal
ampliﬁcations in 4q12 and 12q13.3-q14.1 detected in the grade
IV region, with comparably high copy number and seemingly
identical breakpoints (supplementary Figures S2C and D and S6,
available at Annals of Oncology online). Although the grade II
sample also shared the 12q13.3-q14.1 ampliﬁcation, the entire
4q-arm was ampliﬁed in this sample. SV analysis revealed
complex chromosomal re-arrangements linking the 4q12 and
12q13.3-q14.1 focal ampliﬁcations in the higher grade samples
only. Taken together, these features are reminiscent of a double-
minute chromosome (DM), a relatively frequent cytogenetic
event in GBM [9, 16].
To investigate this further, we employed a precise amplicon
reconstruction method [9]. This involved the identiﬁcation of
breakpoints related to the highly ampliﬁed regions, followed by
the construction of a breakpoint graph that links the ampliﬁed
segments and their associated breakpoints, and a ﬁnal search for
an optimal path that completely traverses the graph (supple-
mentary Figure S9, available at Annals of Oncology online). In
the ﬁnal solution, segment traversal number correlates with
observed relative copy number of the segment, and circular
paths are indicative of a DM.
Consistent with a DM, the 4q12 and 12q13.3-q14.1 ampliﬁca-
tions revealed circular paths, indicating DMs in the grade IV
and recurrence samples (Figure 2A and B and supplementary
Figure S9A, available at Annals of Oncology online). Two
chromosomal intervals (Figure 2A) replete with putative driver
genes (PDGFRA, KIT, CDK4, AVIL and miR-26a-2) are re-
conﬁgured into circular assemblies. Figure 2B illustrates the
optimal paths that account for the observed breakpoints and
high copy-number ampliﬁcations. The absence of this structure
in the grade II sample suggests that the 12q13.3-q14.1 focal
ampliﬁcation preceded DM formation, consistent with a break-
age-bridge fusion cycle [17]. However, L1 elements ﬂank the
12q13.3-q14.1 ampliﬁcation (data not shown), precluding further
local SV resolution. There are numerous precisely shared break-
points between the DM models, and all breakpoints tested vali-
dated (Figure 2C and supplementary Figure S10, available at
Annals of Oncology online), which suggests a common origin of
the extra-chromosomal structures. Moreover, the breakpoints
exhibit features of non-homologous end-joining [8] which may
be indicative of a single chromothriptic event [18].
To investigate the origin of the DMs, we carried out haplotype
analysis in the grade IV and recurrence DMs. This was achieved
using allele frequencies of heterozygous SNPs located in the
DM locus (supplementary Information, available at Annals of
Oncology online). Consistent with a shared origin of the DMs,
the allelic composition of the DM haplotypes appears to be
identical at the 4q12 and 12q13.3-q14.1 loci (supplementary
Figure S11, available at Annals of Oncology online). Moreover,
the DM derived from both higher copy-number haplotypes;
conversely, the higher copy-number haplotypes on 4q12 were
predominantly lost in the segments ﬂanking the DM. Such a
pattern is consistent with shattering of a ‘gained’ chromosome
4q followed by ‘rescue’ of oncogenic fragments within the DM
and loss of the remainder of the chromosome.
double-minute chromosome is associated with
progression
We computed a distance matrix from all the mutations detected
in the primary regions and in the three recurrence regions,
establishing a phylogenetic relationship between the sequenced
regions. This conﬁrmed that the recurrence specimen was most
similar to the grade IV region, with the DM likely arising bet-
ween the grade II and grade IV regions (Figure 3A). The DM
carries the putative GBM driver gene AVIL [19], with a mutation
restricted to the grade IV/recurrence lineage and linked to
the focal ampliﬁcation via discordant paired-end reads as well
as exhibiting a high-variant allele frequency (chr12:58204830;
supplementary Figure S2F, available at Annals of Oncology
online). Additionally, the DM uniﬁes multiple oncogenic com-
ponents of the PI3K pathway: PDGFRA, KIT, and a regulator
of PTEN (miR-26a-2) as well as CDK4 (Figure 2B). To assess if
the grade IV tumour shows increased activation of the PI3K
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pathway, we carried out immunohistochemistry against
PDGFRA, PTEN and cKIT in the grade II and grade IV
tumours (Figure 3B). We found increased levels of PDGFRA
(215/300 versus 93/300, grade IV versus grade II) and cKIT
(222/300 versus 31/300) in the grade IV tumour, but no differ-
ence in the PTEN levels (34/300 versus 23/300). This suggests
that PTEN is deactivated in both the grade II and grade IV
tumours, but that the PI3K pathway is further activated in the
grade IV tumour, likely due to ampliﬁcation of genes encoded
within the DM.
IDH1 driver mutation is lost at recurrence
Trunk events including the TP53 and ATRX mutations and
PDGFRA/KIT, CDK4/miR-26a-2 focal ampliﬁcations along with
the grade IV private mutation detected in AVIL were identiﬁed
at high frequency in the recurrence samples. Surprisingly, the
IDH1 R132H mutation was not detected in the recurrence
samples despite being clonal in the grade II and IV lesions. To
validate this observation, we carried out digital PCR (dPCR) on
IDH1 and TP53 (using TP53 as a control). We conﬁrmed that
the R132H mutation was indeed clonal in the grade II and grade
IV specimens (found in ∼42%–44% of DNA molecules, supple-
mentary File, available at Annals of Oncology online), but essen-
tially undetected in the recurrence samples, with between 0.01%
and 0.1% of DNA molecules showing the mutation by dPCR.
Conversely, TP53 was found in between 8% and 12% of the
DNA molecules (supplementary File, available at Annals of
Oncology online), consistent with clonal presence in the low-
purity recurrence biopsies (estimated at 10%–15% purity, sup-
plementary Information, available at Annals of Oncology
online). It is therefore likely that the recurrence has experienced
loss of the mutated IDH1 allele and retention of the wild-type
allele.
A recent report indicates mutual exclusivity between activa-
tion of the PI3K pathway and IDH1 activity [20]. As the recur-
rence demonstrated increased levels of PDGFRA and KIT
ampliﬁcation encoded on the DM, activators of the PI3K
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Figure 3. Evolution a GBM tumour to recurrence. (A) Phylogenetic tree describing the evolution of the tumour. The length of the branches is calculated using
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of the double minute. Medium grey (blue online) dot represents branching of grade II and grade IV specimens, grey (orange online) dot represents the
genome-doubling event, dark grey (red online) dot represents branching of recurrence tumour from the grade IV specimen. Black dots represent tumour sam-
pling. For IDH1, mutant allele frequency detected by dPCR is indicated in parenthesis (B) Immunohistochemistry showing increased expression of cKIT and
PDGFRA in the grade IV component of the primary tumour relative to grade II. PTEN is highly expressed in the proliferating vessels of both the grade II and
IV primary tumour sectors but the neoplastic astrocytes are largely negative.
Volume 26 | No. 5 | May 2015 doi:10.1093/annonc/mdv127 | 
Annals of Oncology original articles
pathway, we addressed whether the GBM data from The Cancer
Genome Atlas (TCGA) [16] supports mutual exclusivity
between IDH1 R132H mutation and PDGFRA and/or KIT amp-
liﬁcation. IDH1 and TP53 mutations are enriched in the pro-
neural subtype [21]. Using the cBIO portal [22], we identiﬁed
137 TCGA GBM cases classiﬁed as proneural in Brennan et al.
[16], with both sequence and copy-number data. Of these, 12
showed the R132H mutation, 25 showed dual KIT and PDGFRA
ampliﬁcation and 10 showed PDGFRA ampliﬁcation only. No
overlap between cases with the IDH1 R132H mutation and KIT
and/or PDGFRA ampliﬁcation was observed indicating mutual
exclusivity between these oncogenic events (P = 0.036, Fisher’s
exact test). This also suggests that the IDH1 R132H mutation
was indeed an early driver event that was subsequently lost
during recurrence, as a more potent poly-oncogene–oncomir
cluster was selected for in the DM.
An analysis of TCGA GBM data from 264 tumours with
whole-exome sequencing processed by Sanborn et al. [9] to
infer DM structures, identiﬁed four samples, of these three pro-
neural, with ampliﬁcations of both PDGFRA and CDK4, pos-
sibly encoded in double-minute chromosomes. These data
suggest that at least 1.5% (4/264) of GBM tumours overall, and
8% (22/264) of the proneural subtype, are driven by the acquisi-
tion of such a macro-evolutionary event typiﬁed by PDGRA/
CDK4/miR-26a-2 DMs.
discussion
This study is one of the ﬁrst reports of a multi-region longitu-
dinal WGS of a GBM from diagnosis to death, carried out spe-
ciﬁcally with the intention to improve patient outcome by the
application of tailored therapy. Unfortunately, despite identify-
ing multiple ampliﬁed targetable oncogenes and applying tar-
geted therapy, disease control was not achieved, and the patient
died following disease progression.
To our knowledge, this is the ﬁrst description of a loss of a
tier 1 clonal driver event (IDH1, R132H) during disease pro-
gression, and may reﬂect complex epistatic relationships
between tumour somatic events and the selection pressure of
therapy. We cannot formally exclude the possibility that the
IDH1 mutation in the primary samples was a sub clonal event at
diagnosis; we have documented in NSCLC and ccRCC that
drivers can appear clonally dominant within one region only to
ﬁnd that further tumour sampling reveals the sub clonal nature
of the event. However, this would require extensive parallel evo-
lution since the majority of somatic aberrations were shared
between relapse and the grade IV region. Rather, the progressive
enrichment of the DMs from the grade IV to recurrence sug-
gests increased oncogenic potential based on the PI3K pathway.
With the waning of the driver IDH1 event, this indicates a
macro-evolutionary switch from the dominance of the IDH1-
mutated tumour to a DM-driven tumour in a mutually exclusive
context. An analysis of the TCGA data also revealed no overlap
between IDH1 R132H mutations and PDGFRA/KIT ampliﬁcation,
suggesting that high-level PDGFRA/KIT ampliﬁcation would not
be favourable with an existent IDH1 R132Hmutation.
These ﬁndings have important implications for precision
medicine, suggesting a targetable clonal driver event can be se-
lectively lost during the disease course, and replaced in its
entirety by an initially low-frequency event in the primary
tumour. The clonal dominance of IDH1 driver events might
need to be considered within the context of low-frequency
oncogenic drivers when examining the efﬁcacy of therapeutics
targeting IDH1 in this disease [23]. Furthermore, despite rapid
WGS at recurrence and cancer genome-directed therapy, imati-
nib was unable to control the disease. Following radiotherapy and
two surgical debulking procedures, it is unlikely that the blood–
brain barrier was intact, preventing drug penetration into the
central nervous system. It is more likely that treatment failure was
a consequence of the evolution of the poly-oncogene/oncomir
DM targeting the PI3K axis at multiple nodal points.
Moreover, our results emphasize the profound effects of cancer
cell GD, resulting in accelerated cancer genome evolution, charac-
terised by a tolerance of CIN and propagation of aneuploid
progeny [15]. The accelerated CIN permitted following the GD
event in the grade IV region of the primary tumour, and possibly
a chromothripsis event on chromosome 4, resulted in the forma-
tion and subsequent selection of a highly poly-oncogene–
oncomir DM encodingmiR-26a-2, PDGFRA, KIT and CDK4.
MicroRNA miR-26a-2 effectively targets PTEN [24].
Immunohistochemistry demonstrated that PTEN expression
was weak or absent relative to stromal cells in both the grade II
and grade IV regions, although no genomic aberrations were
detected at the PTEN locus. It is likely therefore, that ampliﬁca-
tion of CDK4/miR-26a-2 region, either encoded within the DM
in the grade IV region and recurrent tumour or simply due to
ampliﬁcation as observed in the grade II specimen, directly con-
tributed to loss of PTEN protein expression.
Taken together, these observations emphasise the complexity of
signal transduction cascades activated within individual tumours.
However, it is apparent that the oncogenic drivers involved in
GBM pathogenesis are highly constrained and the combination of
these events involved in DMs may be ﬁnite. There is an unmet
need to enrol patients within longitudinal cohort studies to deﬁne
these genetic constraints in order to accelerate our understanding
of GBM evolution throughout the disease course and optimise
therapeutic opportunities in this disease.
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